Out of 1,400 teams chasing the largest prize ever offered for reversing aging, an Austin gene therapy company made the final ten.
Part of a ten-part series profiling each of the $101 million XPRIZE Healthspan competition’s Milestone 2 Awardees. Across the series, Longevity.Technology examines the science behind each team’s approach, the trial data supporting it and what stands between them and the competition’s final phase.
Seven years, $101 million and one audacious goal: prove, in a controlled human trial, that aging itself can be pushed backward. That’s the premise of XPRIZE Healthspan, the largest incentive competition ever launched in the field of aging research.
When the contest opened, 1,400 teams from 58 countries signed up, chasing a prize that demands something almost no one has delivered convincingly yet: measurable restoration of muscle, cognitive and immune function in adults between 50 and 80, equivalent to turning the clock back a decade or two.
The field narrowed dramatically. Minicircle, a plasmid gene therapy company based in Austin, Texas, was named one of the ten finalists, a distinction that puts it among a small handful of companies XPRIZE judges consider to have a real shot at demonstrating functional age reversal in human trials [1]. Of the original applicant pool, 600 entries made it to a formal review, 40 received seed funding of $250,000 to pursue early proof-of-concept work, and now just ten remain standing.
A different way of editing biology
What separates Minicircle’s approach from more familiar gene therapy is the delivery mechanism. Traditional gene therapies often rely on modified viruses to smuggle genetic material into cells, effective, but carrying real safety tradeoffs, including immune reactions and the inability to easily redose a patient.
Minicircle instead uses small loops of non-viral circular DNA, essentially stripped-down genetic instructions without the viral shell, which the company says can be given repeatedly and can carry instructions for more than one gene at a time.
That matters because aging isn’t caused by a single broken gene or pathway. It’s the product of several systems degrading in parallel, muscle mass eroding, mitochondria losing efficiency, the immune system growing less responsive and low-grade inflammation creeping into aging tissue.
Minicircle’s pitch is that a single, redosable platform capable of hitting multiple targets at once has a better shot at addressing that complexity than treatments built to modulate just one pathway.
“Minicircle’s platform is designed to safely and precisely modulate multiple aging pathways at once,” said Minicircle founder and CEO Mac Davis. “This recognition underscores the transformative potential of programmable gene therapy to enhance vitality and extend the healthy years of life.”
What the finalist spot actually buys
As one of the ten finalists, Minicircle receives $1 million to help fund what the company describes as the largest placebo-controlled interventional human trial yet attempted on the effects of aging, a longitudinal study meant to test whether its combination gene therapy can move the needle on healthspan at scale, not just in a small pilot group.
The company has also drawn financial backing from investors including Peter Thiel, whose interest in extending human healthspan is well documented in longevity circles and has helped pull mainstream capital toward the field over the past decade. For a company working in a space still viewed skeptically by parts of the medical establishment, that kind of validation, both financial and now competitive, carries weight.
The bigger picture for longevity science
XPRIZE Healthspan won’t crown its Grand Prize winners until 2030, once all the competing trials have concluded, so Minicircle’s work is really just beginning in earnest. However, the structure of the competition itself says something about where longevity science is heading: toward interventions judged on a much more human metric, whether people in their 60s, 70s and 80s can move, think and fight off illness the way they did a decade or two earlier.
A treatment that adds years to a lifespan without adding function to those years is a hollow win. The XPRIZE’s insistence on measurable restoration, not just survival, has pushed competing teams, Minicircle included, to design trials around real-world capability rather than lab markers alone.
Whether plasmid gene therapy turns out to be the platform that gets there is still an open question, one that will play out over years of clinical data. But for now, Minicircle has cleared a bar that 1,390 other teams couldn’t, and the field of ten still standing offers a genuine glimpse at where the smart money in anti-aging science is placing its bets.
